CTMX
CytomX Therapeutics, Inc.
$3.84
+0.03 (+0.79%)
At close · Jul 7
Market Cap
$835.98M
Shares
217,702,919
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Elaine V. Jones Ph.D. | Class II director | Appointed | 2026-06-22 |
| Matthew P. Young | Class II director | Appointed | 2026-06-22 |